Cost vs. benefit: The approval of new anti-cancer therapies

Original broadcast date: July 19, 2009

In a recent issue of the Journal of the National Cancer Institute, Drs. Tito Fojo of the National Cancer Institute’s medical oncology division and Christine Grady of the NIH’s bioethics department recommended that studies of cancer drugs that provide two months or less of extended survival should be undertaken only if the treatment costs less than $20,000.

  • Dr. Tito Fojo, M.D., Ph.D. Head, Experimental Therapeutics Section and Senior Investigator, Medical Oncology Branch at the National Cancer Institute’s Center for Cancer Research


Send a Comment